Tango Therapeutics TNGX Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Tango Therapeutics (TNGX) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $134K in Q1 2026.
- How has Tango Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Tango Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 396.3% year-over-year, from $27K to $134K.
- What is the long-term trend for Tango Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 4 years (2021 to 2025), Tango Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -100.0% compound annual growth rate (CAGR), from $766K to $0.